ReviewCritical care clinics2011
Surfactant therapy for acute lung injury and acute respiratory distress syndrome.
Review in Critical care clinics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Safety and efficacy of pulmonary surfactant therapy for acute respiratory distress syndrome in children: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Reassessing adult surfactant replacement therapy with mechanics-informed reinforcement learning.PLoS computational biology · 2026Article
- Surfactant protein SP-B: one ring to rule the molecular and biophysical mechanisms of the pulmonary surfactant system.Biophysical reviews · 2025Review
- New experiments and models to describe soluble surfactant adsorption above and below the critical micelle concentration.Journal of colloid and interface science · 2025Article
- Mechanosensitive channels TMEM63A and TMEM63B mediate lung inflation-induced surfactant secretion.The Journal of clinical investigation · 2024Article
- Synergistic Therapeutic Effects of D-Mannitol-Cerium-Quercetin (Rutin) Coordination Polymer Nanoparticles on Acute Lung Injury.Molecules (Basel, Switzerland) · 2024Article
- Oxidative stress, redox status and surfactant metabolism in mechanically ventilated patients receiving different approaches to oxygen therapy (MecROX): An observational study protocol for mechanistic evaluation.NIHR open research · 2024Article
- Evolution of interfacial mechanics of lung surfactant mimics progression of acute respiratory distress syndrome.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Intrinsic pulmonary sealing, its mechanisms and impact on validity and translational value of lung sealant studies: a pooled analysis of animal studies.Journal of thoracic disease · 2023Article
- HUB genes transcriptionally regulate lipid metabolism in alveolar type II cells under LPS stimulation.Heliyon · 2023Article
- Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.Bioscience reports · 2023Review
- Comparative efficacy of pulmonary surfactant in respiratory distress syndrome in preterm infants: a Bayesian network meta-analysis.Archives of medical science : AMS · 2023Review
- Efficacy of surfactant therapy of ARDS induced by hydrochloric acid aspiration followed by ventilator-induced lung injury - an animal study.Physiological research · 2022Article
- A case report of recreational use of inhaled Freon leading to acute hypoxemic respiratory failure salvaged by veno-venous extracorporeal membrane oxygenation.Canadian journal of anaesthesia = Journal canadien d'anesthesie · 2022Article
- Pulmonary Pharmacokinetics of Polymer Lung Surfactants Following Pharyngeal Administration in Mice.Biomacromolecules · 2022Article
- Management of severe neonatal respiratory distress due to vertical transmission of severe acute respiratory syndrome coronavirus 2: a case report.Journal of medical case reports · 2022Article
- Mechanistic Understanding of Lung Inflammation: Recent Advances and Emerging Techniques.Journal of inflammation research · 2022Review
- Surfactant therapies for pediatric and neonatal ARDS: ESPNIC expert consensus opinion for future research steps.Critical care (London, England) · 2021Article
- Breath-Synchronized Nebulized Surfactant in a Porcine Model of Acute Respiratory Distress Syndrome.Critical care explorations · 2021Article
- The Central Role of Fibrinolytic Response in COVID-19-A Hematologist's Perspective.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
This article examines exogenous lung surfactant replacement therapy and its usefulness in mitigating clinical acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS). Surfactant therapy is beneficial in term infants with pneumonia and meconium aspiration lung injury, and in children up to age 21 years with direct pulmonary forms of ALI/ARDS. However, extension of exogenous surfactant therapy to adults with respiratory failure and clinical ALI/ARDS remains a challenge. This article reviews clinical studies of surfactant therapy in pediatric and adult patients with ALI/ARDS, focusing on its potential advantages in patients with direct pulmonary forms of these syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.